Q-Line Biotech Limited
Q-Line Biotech Limited is a listed company. It booked ₹198 cr of revenue in its latest half year (H2 FY26) and kept 17.4% of sales as profit.
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 59% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,334–2,885 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 59
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in QLINE?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-01.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹198 cr |
| Other Income | ₹3 cr |
| Total Income | ₹201 cr |
| Cost of Materials | ₹49 cr |
| Purchases of Stock-in-Trade | ₹26 cr |
| Inventory Change (±) | ₹-1 cr |
| Employee Benefit Expense | ₹24 cr |
| Finance Costs | ₹11 cr |
| Other Expenses | ₹38 cr |
| Total Expenses | ₹154 cr |
| Profit before Tax | ₹46 cr |
| Tax Expense | ₹12 cr |
| Net Profit | ₹34 cr |
| Net margin on total income | 17.1% |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.